Physician profile
Benjamin Thomas
NPI 1922756584
$2,105.94
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $562 · 2024: $706 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.45 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $240.14 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $215.01 | 2022-2025 | Mounjaro, Zepbound, Humulin |
| Sequel Med Tech, LLC | $179.10 | 2025 | Twiist |
| Insulet Corporation | $169.25 | 2023-2025 | Omnipod |
| Abbott Laboratories | $157.04 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $156.35 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $141.86 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $107.81 | 2023-2024 | Rybelsus, Ozempic |
| Amgen INC. | $82.94 | 2024-2025 | Tepezza |
| Merck Sharp & Dohme LLC | $80.18 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $67.52 | 2025 | |
| Ascensia Diabetes Care US INC. | $53.71 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $51.36 | 2022-2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $43.69 | 2024 | Strensiq |
| Astrazeneca Pharmaceuticals Lp | $42.90 | 2024 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $42.76 | 2023-2024 | Cequr Simplicity |
| E.R. Squibb & Sons, L.L.C. | $38.54 | 2023 | Eliquis, Camzyos |
| Radius Health, INC. | $35.34 | 2022-2025 | |
| Horizon Therapeutics Plc | $31.49 | 2023 | Tepezza |
| Beta Bionics, INC. | $26.01 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| La Jolla Pharmaceutical Company | $25.74 | 2023 | Xerava |
| Amryt Pharma Holdings Ltd | $23.52 | 2023 | Mycapssa |
| Mannkind Corporation | $22.19 | 2023 | Afrezza |
| Chiesi USA, INC. | $20.48 | 2024 | Mycapssa |
| Sanofi-Aventis U.S. LLC | $19.16 | 2023 | |
| Opko Pharmaceuticals, LLC | $16.33 | 2022 | |
| Astellas Pharma US INC | $15.52 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.